// App-Quantinova.ai

P4-21-02 : Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

Researchers

Presenter

  • A Schneeweiss

Principal Investigators

  • S Chia

  • T Hickish

  • V Harvey

  • A Eniu

  • M Waldron-Lynch

  • J Eng-Wong

  • S Kirk

  • J Cortés

Medical Centers

  • Cancer Institute "Prof. Dr Ion Chiricuta", Cluj-Napoca, Romania

  • Royal Bournemouth Hospital, Bournemouth University, Bournemouth, United Kingdom

  • Ramon y Cajal University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada

  • Regional Cancer and Blood Centre, Auckland City Hospital, Auckland, New Zealand

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

Locations

  • Canada

  • Spain

  • Germany

  • United Kingdom

  • Romania

  • New Zealand

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Systolic dysfunction

  • Congestive heart failure

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Fluorouracil

  • Adrucil injection

  • Carboplatin

  • Trastuzumab

  • Epirubicin

  • Pertuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • NCT00976989

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved